Advertisement

Endocrine Pathology

, Volume 21, Issue 3, pp 161–165 | Cite as

MGMT Immunoexpression in Silent Subtype 3 Pituitary Adenomas: Possible Therapeutic Implications

  • Michael E. Fealey
  • Bernd W. ScheithauerEmail author
  • Eva Horvath
  • Dana Erickson
  • Kalman Kovacs
  • Roger McLendon
  • Ricardo V. Lloyd
Article

Abstract

The objective of the study was to assess O 6-methylguanine-DNA methyltransferase (MGMT) immunoreactivity in pituitary adenomas of silent subtype 3 as a potential indicator of temozolomide susceptibility. The Mayo Clinic Anatomic Pathology Database was searched for all cases of silent subtype 3 pituitary adenoma. Each of the 23 cases identified had been confirmed on the basis of histology, immunohistochemical staining for pituitary hormones, as well as on diagnostic ultrastructural criteria. Unstained microscopic sections were immunostained for MGMT and were semiquantitatively assessed. Of the 23 tumors examined, 18 (78%) showed no MGMT immunoreactivity. The remaining five (22%) showed immunoreactivity in ≤50% of tumor cells. Among eight of the most clinically aggressive tumors in this study, six (75%) lacked MGMT immunoreactivity. The observed lack of or low-level expression of MGMT by this distinctive, clinically aggressive form of pituitary adenoma suggests potential efficacy of treatment with the alkylating agent temozolomide.

Keywords

Pituitary adenoma Silent subtype 3 adenoma MGMT expression Temozolomide 

References

  1. 1.
    Erickson D, Scheithauer B, Atkinson J, Horvath E, Kovacs K, Lloyd RV, Young WF, Jr.: Silent subtype 3 pituitary adenoma: a clinicopathologic analysis of the Mayo Clinic experience. Clin Endocrinol (Oxf) 71 (1):92-99, 2009.CrossRefGoogle Scholar
  2. 2.
    Horvath E, Lloyd RV, Kovacs K, Sano T, Kontogeorgos G, Trouillas J, Asa SL (2004). Plurihormonal adenoma. In: RA De Lellis, RV Lloyd, PU Heitz et al. (eds) World Health Organization classification for tumours—pathology & genetics—tumours of endocrine organs. International Agency for Research on Cancer, Lyon, p 35.Google Scholar
  3. 3.
    Horvath E, Kovacs K, Smyth HS, Killinger DW, Scheithauer BW, Randall R, Laws ER, Jr., Singer W: A novel type of pituitary adenoma: morphological features and clinical correlations. J Clin Endocrinol Metab 66 (6):1111-1118, 1988.CrossRefPubMedGoogle Scholar
  4. 4.
    Lillehei KO, Kirschman DL, Kleinschmidt-DeMasters BK, Ridgway EC: Reassessment of the role of radiation therapy in the treatment of endocrine-inactive pituitary macroadenomas. Neurosurgery 43 (3):432-438; discussion 438-439, 1998.CrossRefPubMedGoogle Scholar
  5. 5.
    Osamura RY, Kajiya H, Takei M, Egashira N, Tobita M, Takekoshi S, Teramoto A: Pathology of the human pituitary adenomas. Histochem Cell Biol 130 (3):495-507, 2008.CrossRefPubMedGoogle Scholar
  6. 6.
    Biswas T, Ramana CV, Srinivasan G, Boldogh I, Hazra TK, Chen Z, Tano K, Thompson EB, Mitra S: Activation of human O6-methylguanine-DNA methyltransferase gene by glucocorticoid hormone. Oncogene 18 (2):525-532, 1999.CrossRefPubMedGoogle Scholar
  7. 7.
    Hegi ME, Diserens AC, Gorlia T, Hamou MF, de Tribolet N, Weller M, Kros JM, Hainfellner JA, Mason W, Mariani L, Bromberg JE, Hau P, Mirimanoff RO, Cairncross JG, Janzer RC, Stupp R: MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med 352 (10):997-1003, 2005.CrossRefPubMedGoogle Scholar
  8. 8.
    Kovacs K, Scheithauer BW, Lombardero M, McLendon RE, Syro LV, Uribe H, Ortiz LD, Penagos LC: MGMT immunoexpression predicts responsiveness of pituitary tumors to temozolomide therapy. Acta Neuropathol 115 (2):261-262, 2008.CrossRefPubMedGoogle Scholar
  9. 9.
    Verbeek B, Southgate TD, Gilham DE, Margison GP: O6-Methylguanine-DNA methyltransferase inactivation and chemotherapy. Br Med Bull 85:17-33, 2008.CrossRefPubMedGoogle Scholar
  10. 10.
    Kovacs K, Horvath E, Syro LV, Uribe H, Penagos LC, Ortiz LD, Fadul CE: Temozolomide therapy in a man with an aggressive prolactin-secreting pituitary neoplasm: Morphological findings. Hum Pathol 38 (1):185-189, 2007.CrossRefPubMedGoogle Scholar
  11. 11.
    Moyes VJ, Alusi G, Sabin HI, Evanson J, Berney DM, Kovacs K, Monson JP, Plowman PN, Drake WM: Treatment of Nelson's syndrome with temozolomide. Eur J Endocrinol 160 (1):115-119, 2009.CrossRefPubMedGoogle Scholar
  12. 12.
    Kouwenhoven MC, Kros JM, French PJ, Biemond-ter Stege EM, Graveland WJ, Taphoorn MJ, Brandes AA, van den Bent MJ: 1p/19q loss within oligodendroglioma is predictive for response to first line temozolomide but not to salvage treatment. Eur J Cancer 42 (15):2499-2503, 2006.CrossRefPubMedGoogle Scholar
  13. 13.
    Soffietti R, Leoncini B, Ruda R: New developments in the treatment of malignant gliomas. Expert Rev Neurother 7 (10):1313-1326, 2007.CrossRefPubMedGoogle Scholar
  14. 14.
    Horvath E, Kovacs K, Smyth HS, Cusimano M, Singer W: Silent adenoma subtype 3 of the pituitary--immunohistochemical and ultrastructural classification: a review of 29 cases. Ultrastruct Pathol 29 (6):511-524, 2005.CrossRefPubMedGoogle Scholar
  15. 15.
    Horvath E, Kovacs K, Killinger DW, Smyth HS, Platts ME, Singer W: Silent corticotropic adenomas of the human pituitary gland: a histologic, immunocytologic, and ultrastructural study. Am J Pathol 98 (3):617-638, 1980.PubMedGoogle Scholar
  16. 16.
    Karavitaki N, Ansorge O, Wass JA: Silent corticotroph adenomas. Arq Bras Endocrinol Metabol 51 (8):1314-1318, 2007.PubMedGoogle Scholar
  17. 17.
    Trouillas J, Barkan AL, Watson RE, Jr., Lindell EP, Farrell WE, Lloyd RV. ACTH producing adenoma. In: World Health Organization Classification for Tumours - Pathology & Genetics - Tumours of Endocrine Organs. RA De Lellis; RV Lloyd; PU Heitz et al., editors. Lyon, France: International Agency for Research on Cancer; 2004; p. 26-29.Google Scholar
  18. 18.
    Lloyd RV, Kovacs K, Young WF, Jr., Farrell WE, Asa SL, Trouillas J, Kontogeorgos G, Sano T, Scheithauer BW, Horvath E. Pituitary tumours: Introduction. In: World Health Organization Classification for Tumours - Pathology & Genetics - Tumours of Endocrine Organs. RA De Lellis; RV Lloyd; PU Heitz et al., editors. Lyon, France: International Agency for Research on Cancer; 2004; p. 10-13.Google Scholar
  19. 19.
    Mohammed S, Syro L, Abad V, Salehi F, Horvath E, Scheithauer BW, Kovacs K, Cusimano M: Silent somatotroph adenoma of the pituitary in an adolescent. Can J Neurol Sci 36 (1):123-125, 2009.PubMedGoogle Scholar
  20. 20.
    Syro LV, Uribe H, Penagos LC, Ortiz LD, Fadul CE, Horvath E, Kovacs K: Antitumour effects of temozolomide in a man with a large, invasive prolactin-producing pituitary neoplasm. Clin Endocrinol (Oxf) 65 (4):552-553, 2006.CrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2010

Authors and Affiliations

  • Michael E. Fealey
    • 1
  • Bernd W. Scheithauer
    • 2
    • 6
    Email author
  • Eva Horvath
    • 3
  • Dana Erickson
    • 4
  • Kalman Kovacs
    • 3
  • Roger McLendon
    • 5
  • Ricardo V. Lloyd
    • 2
  1. 1.Mayo Work Study ProgramMayo ClinicRochesterUSA
  2. 2.Division of Anatomic PathologyMayo ClinicRochesterUSA
  3. 3.Department of Laboratory Medicine, St. Michael’s HospitalUniversity of TorontoTorontoCanada
  4. 4.Department of Endocrinology and MetabolismMayo ClinicRochesterUSA
  5. 5.Department of Pathology (Neuropathology)Duke UniversityDurhamUSA
  6. 6.Department of Laboratory Medicine and PathologyMayo ClinicRochesterUSA

Personalised recommendations